According to IMS Health, oncology is expected to become the largest market in pharmaceuticals by 2017, followed by diabetes. Currently, Merck's diabetes portfolio is not very elaborate, but its two major products, Januvia and Janumet, have sustained the company's revenue growth rates after the patent cliff.
According to IMS HEALTH, oncology is expected to become the largest market in pharmaceuticals by 2017, followed by diabetes. Currently, Merck’s diabetes portfolio is not very elaborate, but its two major products, Januvia and Janumet, have shored up the company’s revenue growth rates after the patent cliff. Merck & Co, Stock Analysis, Sales And Marketing, Asthma, Cliff, Pool Slides, Diabetes, Drugs, Health